Alcidion Group Ltd Reconfirms FY26 Guidance and Completes Kyra Acquisition

Alcidion reconfirms record FY26 guidance and completes Kyra patient flow acquisition

Alcidion Group Limited (ASX:ALC) has reconfirmed its FY26 full-year guidance and confirmed the completion of its acquisition of the Kyra flow products business from Telstra Health on 29 June 2026. The dual update points to a strengthening position in the patient flow software market across Australia, New Zealand and the United Kingdom.

For the financial year ending 30 June 2026, the healthcare technology company expects revenue to exceed $50M, EBITDA to exceed $5.0M, and operating cashflow to be broadly in-line with FY25’s $5.8M.

CEO and Managing Director Kate Quirke described the period as a “record year for the business,” a characterisation she attributed to performance to date across all key metrics. Management reconfirmed the guidance with what it described as a “high degree of confidence,” underpinned by long-term contracted revenue.

FY26 guidance reconfirmed across all key metrics

The reconfirmation is a confidence-backed reaffirmation rather than fresh guidance, with the company citing financial performance, cash inflow and contracted revenue as the basis. The structure of the revenue base provides high visibility, with many of the larger contracts extending into the mid-2030s.

A key de-risking factor was the UHSussex contract signed during the quarter. Alcidion has subsequently been paid for the material upfront license fee portion of that contract, which the company said enabled it to reconfirm its expected FY26 earnings with confidence.

The UHSussex contract, a seven-year Miya Precision deal worth approximately $35M with extension rights to $49M over 10 years, also marked the first UK deployment of Alcidion’s virtual care module, creating a potential reference site for further NHS adoption.

For investors, this contracted revenue base is what allows guidance to be reaffirmed rather than revised. Recurring, long-dated revenue in healthcare IT tends to be sticky and predictable.

Kyra acquisition completed and immediately earnings accretive

On 29 June 2026, Alcidion completed the acquisition of the business and assets of Kyra Patient Flow Manager, Kyra Queue Manager and Kyra IQ, collectively the “Kyra flow products,” from Telstra Health. The transaction was first announced to the ASX on 18 May 2026.

The Kyra acquisition terms included a $3.0M upfront payment at a 2.7x EBITDA entry multiple, with more than 90% of Kyra revenue derived from recurring support and maintenance contracts and top-10 customers averaging approximately 10-year relationships.

Key features of the completed acquisition include:

• Adds 33 customers (31 new customers)

• The transaction is immediately earnings accretive (pre synergies)

• Creates future opportunities for Miya Precision and the Kyra customers

• An ongoing relationship is maintained with Telstra Health to leverage the complementary nature of the respective product suites

The acquisition further underpins Alcidion’s position as a leading provider of patient flow solutions in ANZ and the UK. By expanding the customer footprint, the company gains cross-sell potential across its existing product range.

Kate Quirke, CEO and Managing Director

“We are delighted to welcome the Kyra flow products, customers and staff to Alcidion and look forward to further building on our leading position in the Australian patient flow market. The initial reaction from customers has been very positive with our focus now shifting to ensure an efficient integration process coupled with the highest level of customer service. The transaction is immediately earnings accretive (pre synergies) with the ability to create future opportunities for Miya Precision and the Kyra customers.”

What patient flow technology means and why it matters

Patient flow solutions help hospitals manage the movement and capacity of patients as they move through a facility, from admission through to discharge. The aim is to improve operational efficiency and the quality of care by giving clinical and operational teams clearer visibility of bed availability, waiting times and demand.

These tools connect to Alcidion’s flagship Miya Precision platform, which aggregates information to centralised dashboards, supports interoperability between systems, and delivers clinical decision support at the point of care.

For investors, the relevance lies in the revenue model. Long-term contracted revenue in healthcare IT is typically sticky and high-visibility, which helps explain why the company can reconfirm guidance with confidence.

Since listing on the ASX in 2016, Alcidion has acquired multiple healthcare IT companies and now operates across three established markets: Australia, New Zealand and the United Kingdom.

Investment thesis and what comes next

The combination of a long-dated contracted revenue base, an immediately earnings-accretive acquisition, and an expanded customer footprint forms the basis of the company’s case for continued growth. The UHSussex upfront payment and contracts extending into the mid-2030s add visibility to forward earnings.

Near-term focus and milestones include:

• The Q4 FY26 Quarterly Activities Report and Appendix 4C, anticipated on 23 July 2026

• Efficient integration of the Kyra flow products and customer service delivery

• Cross-sell potential between Miya Precision and Kyra customers

• Further geographical expansion, in line with company background

With the acquisition now complete, attention turns to how effectively Alcidion integrates the Kyra customer base and converts cross-sell opportunities into the recurring revenue that supports its growth outlook.

Don’t Miss the Next Healthcare Tech Winner on the ASX

Get FREE breaking ASX healthcare technology news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already ahead of the market and never miss a market-moving announcement. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment news breaks.